Natera Oncology

?? March is Colorectal Cancer (CRC) Awareness Month—a time to show support for patients, survivors, and families impacted by this disease. Through innovative molecular residual disease (MRD) testing and partnerships with advocacy organizations, we are committed to supporting people with CRC. No one should navigate this alone. If you or a loved one has been affected by CRC, we’re here to help. Drop a ?? in the comments to show your support for the CRC community. #ColorectalCancerAwareness #MRDTesting #DressinBlue

Great discussions at the CCGCoP Cancer Genomics Bootcamp in Pasadena! Our session, Expanding patient access to germline testing through Natera’s Oncology Hereditary Cancer Alert Program, was presented by Naterans Kevin Manage, PhD, and Kati Young, MS, CGC. #GermlineTesting #Natera

Medicare now covers Signatera for lung cancer patients. Early detection = early treatment, with potential to deliver huge cost savings and improve outcomes for patients.?Well done Medicare! Another win for cancer care in good ol' USA

March is National #ColorectalCancerAwarenessMonth. Colorectal cancer is the leading cause of cancer death in men, and second for women. Show your support and spread the word by: ?? Sharing on social media ?? Buying merch & advocating wherever you go ?? Wearing blue March 7 for #DressInBlueDay ?? Creating a Facebook fundraiser for the Alliance Get more info at https://lnkd.in/gwwsCYPy Thank you to Olympus Corporation of the Americas and Merck for supporting National Colorectal Cancer Awareness Month.

March is HERE, and it's #ColorectalCancerAwarenessMonth! Ready to make a difference? Here's how you can get involved: 1?? Share Your Story 2?? Post a #StrongArmSelfie: every post = $1 donated to the fight against colorectal cancer. 3?? Join our Community of Champions Comment '??' below if you're ready to take action! For more ways to get involved, visit: https://lnkd.in/geTVK3ps

With today’s news that Medicare will cover Signatera for stage I-III non-small cell lung cancer in surveillance, Signatera is now more accessible to patients living with lung cancer – the most lethal and one of the most common forms of cancer in the United States. Signatera test performance and utility in the surveillance setting for stage I-III NSCLC was validated in three independent peer-reviewed studies to support this coverage determination. The body of evidence continues to grow demonstrating Signatera’s value across a broad range of cancer indications and settings. Read more in our latest press release. https://ow.ly/44Jf50V65LQ

Listen in as two leading GI cancer experts discuss recent, impactful data surrounding the use of tumor-informed MRD testing in colorectal cancer. Our experts will review: ?? The significance of ctDNA analysis and serial testing to potentially improve survival in colorectal cancer ?? Recent data demonstrating how tumor-informed testing can predict which ctDNA-positive patients may benefit from additional therapy ?? How MRD testing may be used to help inform metastatic-directed therapy decision-making Register today: https://ow.ly/Bs5K50V1rWz

Join our upcoming webinar! Listen in as two leading GI cancer experts discuss recent, impactful data surrounding the use of tumor-informed MRD testing in colorectal cancer. Our experts will review: ?? The significance of ctDNA analysis and serial testing to potentially improve survival in colorectal cancer ?? Recent data demonstrating how tumor-informed testing can predict which ctDNA-positive patients may benefit from additional therapy ?? How MRD testing may be used to help inform metastatic-directed therapy decision-making Register today: https://ow.ly/Bs5K50V1rWz #GI #ASCO #ASCOGI #Natera American Society of Clinical Oncology (ASCO) Adham Jurdi Bassel El-Rayes Natera

Which patients are at highest risk of recurrence, and may benefit from additional treatment? Join this upcoming webinar with Oleg Gligich, MD and Michael Krainock, MD, PhD, medical director at Natera, to learn about the clinical utility of Signatera, the most widely utilized MRD assay. Register here: https://ow.ly/iJi450V1rSe

Join us for our ASCO #GU25 Industry expert theater! Dr. Adam ElNaggar will review the latest data demonstrating the evolving role of MRD testing for treatment stratification in patients at high risk of relapse, early recurrence detection, and treatment response monitoring in patients with MIBC, RCC and Testicular Cancer. To learn more: https://ow.ly/8Lhn50USwqw Adam ElNaggar